Figures computed from official regulatory filings — .
Analysttarget 21.27 USD (+65%) · consensus 4.18/5 · 12 buy · 4 hold · 1 sell
Ownershipinsiders 11.21% · institutions 95.73% · short 17.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Biohaven Pharmaceutical Holding Co Ltd. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
22 buys286 sellsbar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Heffernan Michael Thomas | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Tilton John | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Coric Vlad | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| JONES WILLIAM A JR | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Coric Vlad | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| HUGIN ROBERT J | Other | $430.7K | SEC |
| Stock Elyse | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Tilton John | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Clark George C. | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| JONES WILLIAM A JR | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Gentile Kimberly | Other | $1.7M | Unusual size | SEC |
| Conway Charles | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Gentile Kimberly | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Stock Elyse | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Clark George C. | Other | $637.4K | Unusual size | SEC |
| JONES WILLIAM A JR | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Tilton John | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Conway Charles | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| GREGORY JULIA P | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Conway Charles | Other | $3.3M | Unusual size | SEC |
| Coric Vlad | Other | $74M | Unusual size | SEC |
| HUGIN ROBERT J | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| CHILDS JOHN W | Other | $1.5M | SEC |
| Conway Charles | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Mehta Kishan | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |